WO2007142130A1 - マイタケ抽出物及びこれを含む皮脂産生を促進するための組成物 - Google Patents
マイタケ抽出物及びこれを含む皮脂産生を促進するための組成物 Download PDFInfo
- Publication number
- WO2007142130A1 WO2007142130A1 PCT/JP2007/061160 JP2007061160W WO2007142130A1 WO 2007142130 A1 WO2007142130 A1 WO 2007142130A1 JP 2007061160 W JP2007061160 W JP 2007061160W WO 2007142130 A1 WO2007142130 A1 WO 2007142130A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- maitake
- sebum
- composition
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Definitions
- the present invention relates to a novel maitake extract and a composition for promoting sebum production containing the same.
- Sebaceous glands attach to the skin, secrete oily substances called sebum, and form an impermeable membrane on the epidermis surface.
- Sebum is a lipid mixture and contains triglycerides, squalene, aliphatic nuts, free fatty acids, cholesterols, and the like.
- Sebum plays an important role in maintaining the moisture retention of the epidermis, imparting moisture and flexibility to the epidermis, and promoting the strength of the skin. In addition, sebum prevents the skin from being damaged by ultraviolet rays, and foreign substances and allergens also have the effect of protecting the skin.
- an amide of linoleic acid or an ester with a sugar As an active ingredient for promoting sebum production, an amide of linoleic acid or an ester with a sugar
- Patent Document 1 branched chain amino acids
- Patent Document 2 branched chain amino acids
- Extracts of maitake there is known an extract with water or an aqueous solvent such as an extract with water or hot water (Patent Documents 3 to 6) or an extract with hydrous ethanol (Patent Documents 7 and 8). ing. Extracts of maitake with water or aqueous solvents are carcinogenic inhibitors (Patent Literature 4), antioxidants (Patent Literature 5), antifungal agents (Patent Literature 6) and enzyme inhibitors of tyrosinase and oc amylase (Patent Literature 8). ) Can be used.
- Patent Document 1 Japanese Translation of Special Publication 2006—504752
- Patent Document 2 Japanese Translation of Special Publication 2002-521320
- Patent Document 3 Japanese Patent Laid-Open No. 11-75768
- Patent Document 4 Japanese Patent Laid-Open No. 2001-97881
- Patent Document 5 Japanese Unexamined Patent Application Publication No. 2005-220087
- Patent Document 6 Japanese Unexamined Patent Application Publication No. 2004-189737
- Patent Document 7 JP-A-8-131133
- Patent Document 8 Japanese Unexamined Patent Publication No. 2000-319192
- the present invention is to provide a novel maitake extract and a composition containing the same that more effectively promote the production of sebum.
- the present invention is as follows.
- composition for promoting sebum production comprising the maitake extract according to any one of (1) to (3);
- composition according to (4) which is in the form of a cosmetic
- composition according to (4) which is in the form of a medicine.
- Fig. 1 is a photograph showing the effect of maitake extract and agaritas extract on lipid droplet formation in sebaceous cells.
- FIG. 2 shows the amount of sebum in sebaceous cells treated with maitake extract and agaritas extract It is a figure.
- FIG. 3 is a graph showing the effect of maitake extract and agaritas extract on TG production of sebaceous cells.
- FIG. 5 is a photograph showing the effect of agaritas extract on sebum accumulation in sebaceous glands.
- the black ellipse in the tissue slice indicates the sebaceous gland ( ⁇ ).
- FIG. 6 is a diagram showing the amount of sebum in sebaceous cells treated with maitake extract and agaritas extract.
- FIG. 7 is a diagram showing the sebum composition in hamster sebaceous gland cells cultured in the presence of a maitake extract.
- ChoE cholesterol ester (corresponding to cholesterol palmitate used as standard lipid); WaxE, wax ester (corresponding to palmityl palmitic acid used as standard lipid); TG, triacylglycerol (trivalmitin used as standard lipid)
- FFA free fatty acid (corresponding to palmitic acid used as standard lipid); Cho, cholesterol (corresponding to cholesterol used as standard lipid).
- the significance test between each processing by Fisher's multivariate analysis of variance method was used.
- FIG. 8 is a photograph of the skin before and after treatment of subject 5 with a cream containing maitake extract.
- the present invention relates to a maitake extract obtained by extracting dry maitake with pure ethanol.
- Examples of the maitake mushrooms in the present invention include mushrooms belonging to the genus Maitake mushroom, maitake mushroom (Gr ifola frondosa), maitake mushroom (Grifola albicans), mushroom maitake (Grifola umbellatus), tonpimaitake mushroom (Grifola gigantean) and the like.
- the maitake in the present invention is preferably a maitake that is glyphora 'frontosa. Maitake may be either a fruit body or a mycelium, but a fruit body is preferred.
- Dried maitake as a raw material for extraction refers to maitake having a water content of 10% by weight or less.
- the dried maitake has a moisture content of preferably 8% by weight or less, more preferably 7% by weight or less.
- Dried maitake can be obtained by dehydrating and drying raw maitake by any method (for example, sun drying, heat drying, vacuum drying, freeze drying, etc.).
- the dried maitake is preferably in the form of a powder.
- Pure ethanol in the present invention refers to ethanol containing 98.0% by volume or more of ethanol at 15 ° C. Pure ethanol preferably contains 99.0% by volume or more, more preferably 99.5% by volume or more of ethanol.
- Extraction of dried maitake with pure ethanol is performed by adding pure ethanol to dry maitake, which is a raw material, and then stirring at room temperature or under heating for a certain period of time.
- the heating temperature is usually a temperature below the boiling point of ethanol, but can also be a temperature below 120 ° C in a closed container.
- a preferable extraction temperature is room temperature (room temperature).
- the extraction time is not particularly limited, but is, for example, about 5 minutes to 10 hours. Extraction can be performed once or more than once.
- the amount of pure ethanol used in the extraction to dry maitake is 100 to 1000 parts by weight, preferably 200 to 600 parts by weight, more preferably 300 to 500 parts by weight with respect to 100 parts by weight of dry maitake. Part.
- a pure ethanol extract can be obtained by separation means such as filtration with a filter paper or filter cloth or centrifugation.
- the pure ethanol extract of maitake in the present invention may be in the form of the above ethanol extract.
- the pure ethanol extract may be in the form of an extract obtained by removing ethanol entirely or partially from the extract by a conventional method. That is, it may be in the form of an extract powder substantially free of ethanol or an extract paste containing 1 to 50% by weight of ethanol. Extract containing ethanol 10-15 weight 0/0, the storage stability good Ikoto are preferred embodiments.
- Pure ethanol extract is obtained in a yield of 2 to 10% by weight, more specifically 3 to 5% by weight (as solids), based on dry maitake.
- the active ingredient in the pure ethanol extract is unknown.
- the pure ethanol extract contains phospholipids and plant steroids.
- the present invention includes a composition for promoting sebum production comprising the extract.
- the composition of the present invention promotes sebum production, so that the skin retains moisture and moisturizes the skin.
- the skin strength can be promoted, the skin can be prevented from being damaged by ultraviolet rays, and the skin can be protected against foreign substances and allergens. Therefore, the present invention includes a composition for promoting sebum production comprising the above extract in the form of a cosmetic.
- composition of the present invention in the form of a cosmetic may contain conventional carriers, excipients, additives and the like blended in the cosmetic. It can be used as cosmetics for preventing rough skin, improving skin texture, improving skin flexibility, and improving skin moisture retention.
- Cosmetic dosage forms include face-washing (face-washing cream 'form' jelly cream cosmetics, etc.), skin-conditioning (such as lotion 'beauty liquid'), protection (milk's moisturizing cream, etc.), knocking 'oil' massage Cosmetics, base makeup (foundation 'sun powder and other sunscreen' tanning cosmetics, etc.), facial makeup (lipstick, eye shadow, eyeliner, etc.), bathing (soap, body shampoo, bath cosmetics, etc.) Examples include suncare (sunscreen 'tanning cosmetics, etc.) and hair growth' hair restoration (hair growth ⁇ hair tonic etc.).
- An effective amount of a maitake extract is added to these cosmetics, for example, 0.1 to 99.9% by weight, preferably 1 to 99% by weight in terms of extract. The remaining part is blended with conventional carriers, excipients or additives.
- the extract of the present invention has an improving effect on skin disorders or skin diseases caused by a decrease in sebum production. Therefore, the present invention includes a composition for promoting sebum production comprising the above-mentioned extract in the form of an external medicine.
- composition of the present invention in the form of a medicine for external use may contain conventional carriers, excipients, additives and the like blended with the medicine.
- skin disorders or skin diseases resulting from a decrease in sebum production include xeroderma, sebum-reducing dermatitis, monetary dermatitis, and atopic dermatitis.
- pharmaceutical dosage forms include solutions, suspensions, lotions, creams, ointments, gels, and the like.
- An effective amount of maitake extract for example, 0.1 to 99.9% by weight, preferably 1 to 99%, is blended with these external medicines.
- a conventional carrier, excipient, additive or the like is blended.
- Conventional carriers, excipients, or additives blended in cosmetics or medicines include solvents, vegetable oils (for example, almond oil, castor oil, cocoa butter, coconut oil, corn oil, cottonseed oil Linseed oil, olive oil, palm oil, peanut oil, poppy seed oil, rapeseed oil, sesame oil, Edible oils such as soybean oil, sunflower oil and tea seed oil), mineral oil, fatty oil, liquid paraffin, buffer, preservative, wetting agent, chelating agent, antioxidant, stabilizer, emulsifier, suspension Agents, gel formers, ointment bases, suppository bases, penetration enhancers, fragrances, skin protectants and the like.
- vegetable oils for example, almond oil, castor oil, cocoa butter, coconut oil, corn oil, cottonseed oil Linseed oil, olive oil, palm oil, peanut oil, poppy seed oil, rapeseed oil, sesame oil
- Edible oils such as soybean oil, sunflower oil and tea seed oil
- mineral oil for example, almond oil, castor
- the solvent includes, but is not limited to, water, alcohol, polyethylene glycol, propylene glycol, glycerol, liquid polyalkylsiloxane, and mixtures thereof.
- the buffer includes, but is not limited to, citrate, acetic acid, tartaric acid, lactic acid, hydrogen phosphate, jetylamine, and mixtures thereof.
- Wetting agents include glycerin, propylene glycol, pentylene glycol, sorbitol
- Lactic acid Lactic acid, urea, BG (1,3-butylene glycol), soybean sterol and mixtures thereof, but are not limited to these.
- the chelating agent includes, but is not limited to, EDTA sodium, citrate, and mixtures thereof.
- Antioxidants include, but are not limited to, butylated hydroxyanisole (BHA), ascorbic acid and its derivatives, tocopherol and its derivatives, cysteine, and mixtures thereof.
- BHA butylated hydroxyanisole
- natural rubber for example, acacia gum
- tragacanth gum for example, tragacanth gum
- xanthan gum for example, soybean lecithin
- sorbitan monooleate derivative for example, wool fat; wool alcohol
- sorbitan ester for example, monoglyceride
- fatty acid esters e.g. triglycerides of fatty acids such as tri (force prill Z force purinate) glyceryl, glyceryl stearate (SE)
- SE force prill Z force purinate
- SE glyceryl stearate
- Suspending agents include cellulose and its derivatives (for example, carboxymethylcellulose, hydroxyethinoresenorelose, hydroxypropenoresenorelose, hydroxypropinoremethylcellulose, etc.), strong ragenan, acacia gum, gum arabic, Forces including, but not limited to, tragacanth and mixtures thereof.
- Gel base and thickening component include liquid paraffin, polyethylene, fatty oil, colloidal silica. Force or aluminum, zinc soap, glycerol, propylene glycol, tragacanth, carboxybule polymer, magnesium aluminum silicate, hydrophilic polymer (eg cellulose derivatives such as starch, carboxymethylcellulose, hydroxyethyl cellulose and other cellulose derivatives), Forces that include water-swellable hydrocolloids, carrageenan, hyaluronate (eg, hyaluronic acid gels that selectively contain sodium chloride), alginate (eg, propylene glycol alginate), and mixtures thereof. There is no limit.
- hydrophilic polymer eg cellulose derivatives such as starch, carboxymethylcellulose, hydroxyethyl cellulose and other cellulose derivatives
- Forces that include water-swellable hydrocolloids eg, carrageenan, hyaluronate (eg, hyaluronic acid gels
- Ointment bases include beeswax, paraffin, cetanol, cetyl palmitate, cetearyl alcohol, polyglyceryl stearate-10, stearic acid, PEG-150 stearate, plant oil, fatty acid sorbitan ester, polyethylene glycol, fatty acid
- Ointment bases include, but are not limited to, condensation products between sorbitan ester and ethylene oxide (for example, polyoxyethylene sorbitan monooleate) and mixtures thereof.
- Hydrophobic ointment bases include, but are not limited to, paraffins, vegetable oils, animal fats, synthetic glycerides, waxes, lanolin, liquid polyalkylsiloxanes and mixtures thereof.
- the hydrophilic ointment base includes a force such as solid macrogol (polyethylene glycol), but is not limited thereto.
- conventional carriers, excipients, or additives include squalene, lecithin, hydrogenated lecithin, ascorbyl tetrahexyldecanoate, allantoin, glycyrrhizic acid 2K, glycosyl trehalose, hydrolyzed hydrogenated starch, hydrolyzed collagen Examples include rose extract, dimethicone, caprylyldaricol, betaine, sodium stearyl glutamate, wild rose oil, batyl alcohol, and proxy proline.
- the present invention also includes a composition for activating sebaceous cells containing the extract.
- Sterilized dry powder of maitake (water content: 6% by weight, maitake made by Hokuto Co., Ltd.) 4000 g of pure ethanol (water content: 99.5% by volume or more) is added to lOOOOg and heated at a temperature of 20 ° C for 18 hours. Extracted with stirring. The residue was removed by centrifugation, and the resulting supernatant was filtered through filter paper. The resulting filtrate was also evaporated to remove ethanol to obtain pure ethanol extract of maitake (yield 43.2 g, internal solid content 37.2 g and ethanol 6. Og).
- Dulbecco's modified Eagle's medium with male golden hamster (5-week-old: purchased from SLC Japan) left and right auricles excised and supplemented with penicillin G (lOOunitsZml) and streptomycin sulfate (100 gZml) , DMEM) (manufactured by Invitrogen), left at 4 ° C. for 1 hour or longer, and then washed with a phosphate buffer (PBS ( ⁇ )). The hair around the auricle was shaved, chopped to about 5x5mm, and left in a 4unitsZml dispase solution (manufactured by Godo Shusei Co., Ltd.) at 4 ° C for 13.5 hours.
- PBS phosphate buffer
- Sebocyte growth (SG) medium [6% (v / v) womb fetal serum (Nichirei Biosciences, Inc.) ) / 2% (v / v) human serum (ICN Biomedical) / 0. 68mM L—glutamine ZlOO units / ml penicillin GZlOO ⁇ gZml streptomycin sulfate ZDMEMZF—12] and sebaceous gland isolated under stereo microscope did.
- Mouse 3T3 cells (purchased from RIKEN Cell Bank) were treated for 4 hours with mitomycin C, seeded in 60mm culture dishes at 1 xl0 3 cellsZcm number of cells 2, and a feeder layer for culturing hamster sebaceous cells.
- the isolated sebaceous glands were attached onto the feeder cell layer using tweezers and cultured until almost confluent at 37 ° C and 5% CO. cell
- the maitake extract 100, 200 and 200 obtained in Example 1 in the presence or absence of insulin ( ⁇ ) (manufactured by Shima Aldrich) was used.
- 400 ⁇ g / ml) or agarita extract 100, 200 and 400 ⁇ g / ml) (6% urine fetal serum Z2% human serum ZO. 68 mM L—glutamine ZlOOunitsZml penicillin
- the cells were treated with GZlOO / zg / ml streptomycin sulfate ZDMEMZF—12). The same treatment was carried out 3 days later, and further cultured for 3 days. In all experiments, cells up to passage number 3 were used.
- oil red O-stained cells were converted into digital images under an optical microscope, and the images were analyzed and quantified using Lumina Vision Ver 2.2.2 (Mitani Corporation). The amount of accumulated sebum was quantified and expressed as an image unit (unit) indicating the amount.
- TGs triacylglycerol
- treatment sample 1 [1. 65 IU / ml glycerol kinase Z6IUZml glycerol-3 phosphatooxidase Z catalase Z2.
- 95 molZml disodium adenosine-5, monotriphosphate, trihydrate (ATP) ZO 65 / z molZml Sodium N— (3,5 Dimethyoxyphenyl) N, —Succinylethylenediamine (DOSE)] was added and reacted at 37 ° C for 10 minutes to release free glycerol. Removed.
- Treatment solution 2 [0.55 IU / ml lipoprotein lipase / peroxidase / 0.65 / z molZml 4-aminoaminopyrine (4 AA)] was immediately added, and the mixture was further reacted at 37 ° C for 10 minutes. After completion of the reaction, the absorbance at 590 was measured. The amount of TGs was calculated from the absorbance of the same triolein standard solution (0.6 mgZml). Incidentally, the amount of DNA of a cell grinding the sample 3, 5-Jiamino using benzoic acid disalt acid (DABA) method was measured and calculated as TGs amount per 1 mu ⁇ DNA.
- DABA benzoic acid disalt acid
- Maitake extract has a sebum production promoting effect in vivo and in vitro. It was also found that this promoting effect is stronger than that of Agaritas. In other words, the maitake extract is a powerful substance for promoting sebum production, and is expected to be effective not only in the care of dry skin but also in reducing the pathological conditions of skin diseases caused by sebaceous gland function decline such as xerosis.
- Hamster sebaceous cells are seeded in a 35 mm culture dish at a cell count of 2. 35xl0 4 cells / cm 2 and the maitake extract (100, 200, 400 ⁇ g / ml) obtained in Example 1 from the next day alone or Sebaceous Cell Culture Medium (SBCM) Containing Both Mushroom Extract and Insulin ( ⁇ ) [DME MZF— 12Z6% (vZv) Fetal Bovine Serum Z2% (vZv) Human Serum ZO. 68 mM L Glutamine Z Penicillin G (100unitsZml ) Z-sulfate streptomycin (100 gZml)] was cultured for 3 days. Cells were harvested after culturing for another 3 days in SBCM containing the same maitake extract alone or both maitake extract and insulin newly prepared 3 days later. In addition, cells cultured in a culture solution containing no maitake extract and insulin were used as controls.
- SBCM Sebaceous Cell Culture Medium
- Sebaceous cells cultured in the presence or absence of maitake extract are washed twice with PBS (—) and 1.5 ml of 0.25% (wZv) trypsin ZO. 02% (wZv) EDTAZPBS ( ⁇ ) solution is used. And recovered.
- the obtained cell suspension is subjected to ultrasonic treatment (200W, 6 seconds) for 5 minutes using ice-cooled closed ultrasonic cell crusher (Bioruptor, manufactured by Cosmo Bio) for sebum composition analysis It was set as the sample of this.
- the obtained sample was transferred to a degreased Spitz tube, and lipid was extracted by adding a black mouth form: methanol (2: 1; v: v) solution.
- each lipid was used as a known amount of standard lipid, and tripalmitin (corresponding to TG in FIG. 7), palmitic acid (corresponding to FFA in FIG. 7), cholesterol (corresponding to Cho in FIG. 7). ), Cholesterol corresponding to cholesterol palmitate (corresponding to ChoE in Fig. 7) (Dosan 'Sedari' Research) and palmityl palmitic acid (corresponding to WaxE in Fig. 7) (Nucheck 'prep') Analyzed from the graph. The amount of each lipid was also calculated as the peak area force of cholesterol acetate (2 g) (manufactured by Dothan “Serdari” Research) used as an internal standard.
- a cosmetic cream containing a maitake extract was prepared with the following composition.
- a medicinal cream containing a maitake extract was prepared with the following composition.
- the following shows the degree of diagnostic evaluation (3: severe 2: moderate 1: mild) of the skin condition of the subject 1 week after the start of application.
- the diagnostic evaluation degree: 0 indicates complete cure.
- the diagnostic evaluation degree of the skin condition of subjects 1 to 12 after the start of application showed improvement.
- a significant symptom-improving effect by applying the maitake extract-containing cream was observed 1 to 3 days after application.
- FIG. 8 is a photograph of the skin before and after treatment of subject 5 with a cream containing maitake extract. Treatment with the application of cream containing Maitake extract improved dry skin symptoms.
- the composition of the present invention is useful as a cosmetic or a medicament for treating skin abnormalities / disorders or diseases caused by a decrease in sebum production.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008520531A JP4677033B2 (ja) | 2006-06-02 | 2007-06-01 | マイタケ抽出物及びこれを含む皮脂産生を促進するための組成物 |
KR1020147020771A KR20140101875A (ko) | 2006-06-02 | 2007-06-01 | 잎새버섯 추출물 및 이를 함유하는 피지 산생을 촉진하기 위한 조성물 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006154912 | 2006-06-02 | ||
JP2006-154912 | 2006-06-02 | ||
TW96106077 | 2007-02-16 | ||
TW96106077 | 2007-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007142130A1 true WO2007142130A1 (ja) | 2007-12-13 |
Family
ID=38801386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/061160 WO2007142130A1 (ja) | 2006-06-02 | 2007-06-01 | マイタケ抽出物及びこれを含む皮脂産生を促進するための組成物 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP4677033B2 (ja) |
KR (2) | KR20090029750A (ja) |
TW (1) | TW200806304A (ja) |
WO (1) | WO2007142130A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009063885A1 (ja) * | 2007-11-13 | 2009-05-22 | Heimat Co., Ltd. | マイタケ抽出物及びこれを含むヒアルロン酸(ヒアルロナン)産生を促進するための組成物 |
WO2014008353A2 (en) | 2012-07-05 | 2014-01-09 | Nutramax Laboratories, Inc. | Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder |
JP2015124182A (ja) * | 2013-12-26 | 2015-07-06 | 日本メナード化粧品株式会社 | 皮脂合成促進剤 |
JP2015124185A (ja) * | 2013-12-26 | 2015-07-06 | 日本メナード化粧品株式会社 | 皮脂合成促進剤 |
JP2019038766A (ja) * | 2017-08-24 | 2019-03-14 | 佐藤 隆 | 皮脂産生促進剤 |
WO2022251524A1 (en) | 2021-05-26 | 2022-12-01 | Nutramax Laboratories, Inc. | Compositions comprising sulforaphane or a sulforaphane precursor and moringa plant components |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02121905A (ja) * | 1988-10-30 | 1990-05-09 | Narisu Keshohin:Kk | 化粧料 |
JPH11263732A (ja) * | 1998-03-16 | 1999-09-28 | Ichimaru Pharcos Co Ltd | キノコ類抽出物含有皮膚外用剤 |
JP2000319192A (ja) * | 1999-05-03 | 2000-11-21 | Kirindo:Kk | 酵素阻害剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1170015A1 (de) * | 2000-07-06 | 2002-01-09 | Laboratoires Serobiologiques(Societe Anonyme) | Verwendung von Extrakten des Pilzes Grifola frondosa |
-
2007
- 2007-06-01 KR KR1020087032104A patent/KR20090029750A/ko active Search and Examination
- 2007-06-01 JP JP2008520531A patent/JP4677033B2/ja active Active
- 2007-06-01 WO PCT/JP2007/061160 patent/WO2007142130A1/ja active Application Filing
- 2007-06-01 KR KR1020147020771A patent/KR20140101875A/ko active Search and Examination
- 2007-06-01 TW TW096119746A patent/TW200806304A/zh not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02121905A (ja) * | 1988-10-30 | 1990-05-09 | Narisu Keshohin:Kk | 化粧料 |
JPH11263732A (ja) * | 1998-03-16 | 1999-09-28 | Ichimaru Pharcos Co Ltd | キノコ類抽出物含有皮膚外用剤 |
JP2000319192A (ja) * | 1999-05-03 | 2000-11-21 | Kirindo:Kk | 酵素阻害剤 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009063885A1 (ja) * | 2007-11-13 | 2009-05-22 | Heimat Co., Ltd. | マイタケ抽出物及びこれを含むヒアルロン酸(ヒアルロナン)産生を促進するための組成物 |
WO2014008353A2 (en) | 2012-07-05 | 2014-01-09 | Nutramax Laboratories, Inc. | Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder |
EP3666277A1 (en) | 2012-07-05 | 2020-06-17 | Nutramax Laboratories, Inc. | Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder |
JP2015124182A (ja) * | 2013-12-26 | 2015-07-06 | 日本メナード化粧品株式会社 | 皮脂合成促進剤 |
JP2015124185A (ja) * | 2013-12-26 | 2015-07-06 | 日本メナード化粧品株式会社 | 皮脂合成促進剤 |
JP2019038766A (ja) * | 2017-08-24 | 2019-03-14 | 佐藤 隆 | 皮脂産生促進剤 |
JP7041913B2 (ja) | 2017-08-24 | 2022-03-25 | 隆 佐藤 | 皮脂産生促進剤 |
WO2022251524A1 (en) | 2021-05-26 | 2022-12-01 | Nutramax Laboratories, Inc. | Compositions comprising sulforaphane or a sulforaphane precursor and moringa plant components |
Also Published As
Publication number | Publication date |
---|---|
JP4677033B2 (ja) | 2011-04-27 |
TWI379684B (ja) | 2012-12-21 |
KR20140101875A (ko) | 2014-08-20 |
JPWO2007142130A1 (ja) | 2009-10-22 |
TW200806304A (en) | 2008-02-01 |
KR20090029750A (ko) | 2009-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI381834B (zh) | Abnormal protein removal composition | |
JP7309620B2 (ja) | 皮膚及び/又は粘膜を水和させるためのネフェリウム・ラパセウム(nephelium lappaceum)の果皮の抽出物の使用 | |
JPWO2004085429A1 (ja) | I型コラーゲン及び/又はエラスチン産生促進用組成物 | |
JP4677033B2 (ja) | マイタケ抽出物及びこれを含む皮脂産生を促進するための組成物 | |
US11529370B2 (en) | Use of composition comprising stem cell-derived exosome as effective ingredient in strengthening skin barrier and improving skin barrier function | |
EP3960154A1 (en) | Functional composition containing immortalized stem cell-derived exosome-rich culture medium and rosebud extract as active ingredients | |
JP2022511023A (ja) | シスツス・モンスペリエンシス(Cistus monspeliensis)の抽出物の新規な化粧品的及び皮膚科学的使用 | |
JP2010520232A (ja) | 玄参抽出物を含有する外用剤組成物及びその皮膚保湿化粧料としての用途 | |
KR101929657B1 (ko) | 밀배아 발효물의 추출물을 유효성분으로 함유하는 피부 주름 개선 외용제 조성물 | |
TWI601540B (zh) | Human Skin Epidermal Cell Proliferator, Compositions Containing Its Skin, and Cosmetic Ingredients | |
JP4583501B2 (ja) | マイタケ抽出物及びこれを含むヒアルロン酸(ヒアルロナン)産生を促進するための組成物 | |
US8637075B2 (en) | Colostrum composition | |
ITRM20130657A1 (it) | Trattamento delle dermatopatie mediante estratto vegetale di daphne laureola | |
US20240197803A1 (en) | Use of mangosteen fruit shell extract in the preparation of a medicament for treating psoriasis | |
KR101481208B1 (ko) | 크립토탄시논을 유효성분으로 함유하는 피부 외용제 조성물 | |
US8637093B2 (en) | Composition and uses thereof | |
JP6364281B2 (ja) | 皮膚老化予防又は改善剤 | |
JP6249516B2 (ja) | トランスグルタミナーゼ活性化剤 | |
KR101864720B1 (ko) | 꿀풀 추출물을 유효성분으로 포함하는 피부결 손상 및 피부 위축증 예방, 개선 또는 치료용 조성물 | |
JP7408269B2 (ja) | メラノソーム分解促進剤 | |
KR20210152372A (ko) | 지방세포 분화 억제제 및 이를 포함하는 조성물 | |
PEDERSEN et al. | Patent 2773277 Summary | |
KR20100048969A (ko) | 저 자극 효과를 갖는 여주 추출물을 함유하는 화장료조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07744548 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008520531 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087032104 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07744548 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020147020771 Country of ref document: KR |